CD274 and neoplasm: Our current study did not elucidate a combinatorial effect in terms of tumor growth between SHP099 and α-PD-L1, which might require further dosage optimization and timing, but we did observe the combination group achieved faster regression in pulmonary tumor burden, which could be a benefit from combination therapy (50, 51, 54).